Replimune Group, Inc. (REPL) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Woburn, MA, 美国. 现任CEO为 Sushil Patel.
REPL 拥有 IPO日期为 2018-07-20, 479 名全职员工, 在 NASDAQ Global Select, 市值为 $161.02M.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
